Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases

Clinical Immunology

Volumn 123, Issue 1, 2007, Pages 60-65

  Kibiki, Gibson S ^a   van der Ven, Andre J A M ^b   Geurts Moespot, Anneke ^b   Shao, John ^a   Calandra, Thierry ^c   Sweep, Fred C G J ^b   Dolmans, Wil M V ^b  

^a Endoscopy Unit   (Tanzania)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

BAL; CD4 count; HIV; MIF; Mortality; Pulmonary TB; Serum

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG DISEASE; LUNG LAVAGE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TANZANIA;

BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; LUNG DISEASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; TANZANIA; TUBERCULOSIS, PULMONARY;

EID: 33947266534     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.12.004     Document Type: Article

References (28)

1. Calandra T., and Roger T. Macrophage migration inhibitory factor: a regulatory of innate immunity. Nat. Rev., Immunol. 3 (2003) 791-800
2. Calandra T., and Bucala R. Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit. Rev. Immunol. 17 (1997) 77-88
3. Nishihira J. Novel pathophysiological aspects of MIF (review). Int. J. Mol. Med. 2 (1998) 17-28
4. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., Gemsa D., Donney T., and Bucala R. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 7849-7854
5. Bernhagen J., Bacher M., Calandra T., Metz C.N., Dotty S.B., Donney T., and Bucala R. An essential role for macrophage inhibitory factor in the tuberculine delayed-type hypersensitivity reaction. J. Exp. Med. 183 (1996) 277-282
6. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., Lane J.S., Craft J., Nishihira J., Donnelly S.C., Zhu Z., and Bucala R. Role of macrophage migration inhibitory factor in asthma. Proc. Natl. Acad. Sci. 102 (2005) 14410-14415
7. Nishihira J. macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J. Interferon Cytokine Res. 20 (2000) 751-762
8. Baugh J.A., and Bucala R. Macrophage migration inhibitory factor. Crit. Care Med. 30 (2002) S27-S35
9. Calandra T., Froidevaux C., Martin C., and Roger T. Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis. JID 187 (2003) S390
10. Yamada G., Shijubo N., Takagi-Takahashi Y., Nishihira J., Mizue Y., Kikuchi K., and Abe S. Elevated levels of serum macrophage migration inhibitory factor in patients with pulmonary tuberculosis. Clin. Immunol. 104 (2002) 123-127
11. Singh M.M. Immunology of tuberculosis-an update. Ind. J. Tub. 46 (1999) 167-169
12. Oddo M., Calandra T., Bucala R., and Meylan P.R.A. Macrophage migration inhibitory factor reduces the growth of virulent Mycobacterium tuberculosis in human macrophages. Infect. Immun. 73 (2005) 3783-3786
13. Beishuizen A., Lambertus T.G., Haanen C., and Vermes I. macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J. Clin. Endocrinol. Metab. 86 (2001) 2811-2816
14. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hultner L., Heumann D., Manuel D., Bucala R., and Glauser M.P. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6 (2000) 164-170
15. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., Manogue K.R., Cerami A., and Bucala R. MIF in pituitary-derived cytokine that potentiates lethal toxaemia. Nature 365 (1993) 756-759
16. Bozza M., Satokar A.R., Lin G., Lu B., Humbles A.A., Gerard C., and David J.R. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189 (1999) 341-346
17. Cobertt E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., and Dye C. The global burden of tuberculosis: global trend and interactions with the HIV epidemic. Arch. Intern. Med. 163 (2003) 1009-1021
18. Butcher H.C., Griffith L.E., Guyatt G.H., Sudre P., Naef M., Sendi P., and Battegay M. Isoniazid prophylaxis for tuberculosis with in HIV infection: meta-analysis of randomized controlled trials. Aids 13 (1999) 501-507
19. Daley C.L., Small P.M., Schecter G.F., Schoolnik G.K., McAdam R.A., Jacobs Jr. W.R., and Hopewell P.C. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficieny virus: an analysis using restriction-fragment-length-polymorphisms. N. Engl. J. Med. 326 (1992) 231-235
20. Cantwell M.F., and Binkin N.J. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and the National Tuberculosis Control Program quality. Tuber. Lung Dis. 77 (1996) 220-225
21. Aliyu M.H., and Salihu H.M. Tuberculosis and HIV disease: two decades of a dual epidemic. Wien Klin. Wochenschr. 115 (2003) 685-697
22. Ole-Nguyaine S., Crump J.A., Kibiki G.S., Kiang K., Taylor J., Schimana W., Bartlett J.A., Shao J.F., Hamilton J.D., and Thielman N.M. HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. Ann. Trop. Med. Parasitol. 98 (2004) 171-179
23. Kox L.F., Rhienthong D., Miranda A.M., Udomsantisuk N., Ellis K., van Leeuwen J., Heusden vanS., Kuijper S., and Kolk A.H. A more reliable PCR for detection of Mycobacterium tuberculosis in clinical samples. J. Clin. Microbiol. 32 (1994) 672-678
24. Grebenschikov N., Geurts-Moespot A., de Witte H., Heuvel J., Leake R., Sweep F., et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators and their inhibitor type I in breast tumor cytosols. Int. J. Biol. Markers 12 (1997) 6-14
25. Grebenschikov N., Sweep C.G., Geurts-Moespot A., et al. An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J. Immunol. Methods 268 (2002) 219-231
26. Ambroziak J.A., Blackbourn D.J., Herndier B.G., Glogau R.G., Gullet J.H., McDonald A.R., Lennette E.T., and Levy J.A. Herpes-like sequence in HIV-infected and uninfected Kaposi's sarcoma patients. Science 268 (1995) 582-583
27. Garrait V., Cadranel J., Esvant H., Henry I., Morinet P., Mayaud C., and Israel-Biet D. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J. Immunol. 159 (1997) 2824-2830
28. Toosi Z., Manyanja-Kizza H., Hirsch C.S., Edmonds K.L., Spahlinger T., Hom D.L., Aung H., Mungyenyi P., Ellner J.J., and Whalen C.W. Impact of tuberculosis on HIV-1 activity in dually infected patients. Clin. Exp. Immunol. 123 (2001) 233